PFAS Litigation Hits 15,000 Cases as Settlement Deadlines Approach

As of January 2026, 15,216 personal injury lawsuits are pending in MDL 2873 in the District of South Carolina. Municipal water authorities face a March 31, 2026 deadline to file Phase 2 claims to receive allocations from over $12 billion in public water system settlements already finalized with chemical manufacturers.

The broad scope of environmental contamination drives active case volumes. EPA monitoring indicates that 165 million Americans reside in areas with measurable PFAS levels in municipal water supplies, with contamination verified in all 50 states. Annual healthcare costs associated with PFAS-related illnesses are estimated at $37 to $59 billion nationally.

Background on AFFF and Personal Injury Claims

Per- and polyfluoroalkyl substances (PFAS) are synthetic fluorinated compounds manufactured since the 1940s. Their stable carbon-fluorine bonds prevent natural environmental degradation.

Personal injury claims largely stem from aqueous film-forming foam (AFFF), a firefighting agent used extensively by the Department of Defense, municipal airports, and industrial facilities. Runoff from fire training sites infiltrated underlying groundwater aquifers. The International Agency for Research on Cancer classified firefighting as a Group 1 human carcinogen in 2022, and occupational studies confirm elevated serum PFAS concentrations in exposed personnel.

Public water system claims have moved through substantial settlement resolutions. 3M entered into a $10.3 billion settlement with public water providers, while DuPont, Chemours, and Corteva agreed to a $1.185 billion resolution. In August 2025, New Jersey finalized an $875 million state natural resources settlement.

By contrast, individual personal injury and occupational exposure claims remain in active discovery without a global settlement framework.

Parallel Procedural Tracks in 2026

Firms managing PFAS dockets are navigating two concurrent procedural schedules:

Municipal Settlement Deadlines

The National League of Cities confirmed key Phase 2 filing deadlines for water system claimants:

• March 31, 2026: Testing Claims reimbursement (3M and DuPont)
• June 30, 2026: DuPont Action Fund Claims
• July 31, 2026: 3M Action Fund Claims
• August 1, 2026: Special Needs Fund Claims (3M and DuPont)

Water authorities that miss these cutoffs forfeit their allocated settlement portions and are barred from future water contamination claims against settling defendants.

Personal Injury Bellwether Trials

The initial personal injury bellwether trial, originally set for late 2025, was rescheduled after Judge Gergel established supplemental case management windows to process newly filed claims. Bellwether trials in 2026 will establish valuation benchmarks across claimant exposure categories.

Proposed settlement matrices categorize claims by exposure intensity and pathology:

• Tier 1: Documented occupational exposure combined with kidney or testicular cancer ($200,000 to $600,000 projected valuation).
• Tier 2: Secondary occupational or documented high-level residential exposure with ulcerative colitis or thyroid cancer ($150,000 to $200,000).
• Tier 3: Residential exposure with limited biomarker verification (projected below $75,000).

Evidentiary and Medical Record Complexity

PFAS claims involve multi-decade latency intervals between chemical exposure and clinical diagnosis.

A claimant diagnosed with renal cell carcinoma in 2024 often requires military service records from the 1990s, occupational exposure logs, baseline blood panel histories, and pathology reports from multiple regional medical centers.

Retrieving and verifying these multi-source records early ensures claims are accurately tiered before bellwether outcomes determine settlement criteria.

Federal Regulatory Standards

The EPA confirmed it will maintain National Primary Drinking Water Regulations for PFOA and PFOS at 4 parts per trillion, while extending compliance deadlines to 2031 for certain alternative compounds (PFNA, PFHxS, GenX chemicals, and PFBS).

This regulatory distinction reinforces general causation evidence for legacy PFOA and PFOS claims, while requiring specific exposure modeling for newer chemical replacements.

Strategic Priorities for Law Firms

Preparing PFAS Inventories for 2026 Bellwethers

With bellwether trials approaching and municipal settlement windows closing, litigation teams are auditing active PFAS inventories to verify proof of exposure and pathology.

Firms with verified oncology reports, serum lab records, and complete provider histories will be prepared to position claims within settlement tiers as federal trials conclude.

Because medical record retrieval is a dedicated case cost, itemized per-case invoices flow directly onto settlement statements upon resolution.

Sources: National League of Cities, Lawsuit Information Center, Drugwatch, EPA, Environmental Working Group, NRDC, PubMed, Lexitas. PFAS MDL case data from court filings in MDL 2873, District of South Carolina.